cbdMD shares rise 10.85% intraday after Q1 2026 earnings call highlights strategic acquisitions and financial growth.

cbdMD Inc. (YCBD) surged 10.85% intraday following a series of positive developments, including strategic acquisitions, revenue growth, and regulatory progress. Recent news highlighted the company’s Q1 2026 earnings call, which emphasized improved liquidity and a strong start to fiscal 2026, alongside the acquisition of Bluebird Botanicals and expansion into Louisiana. Additionally, cbdMD’s compliance with NYSE American listing standards and product innovations, such as Inferno Freeze, reinforced investor confidence. These initiatives collectively underscored the company’s operational resilience and growth potential, aligning with the intraday price surge.